Proposal deadline: Friday, May 29, 2020*
*LOIs do not need to be submitted to the PI’s Contract and Grants officer in OSR or the Research Process Manager in RMG for approval. All application materials must be submitted through the online application portal:
Eligibility: All Stanford faculty with PI eligibility
Purpose: Stanford University’s Innovative Medicines Accelerator (IMA) aims to accelerate the prototyping of innovative medicines, and to enable hypothesis-driven studies on human subjects. The purpose of this request for proposals (RFP) is to leverage emerging capacity and infrastructure at Stanford to address the current COVID-19 pandemic.
COVID-19 Response: Request for Proposals for Drug and Vaccine Prototyping: Through this RFP, IMA seeks to support translational research projects that will develop scalable drug screening assays, validate novel drug targets, repurpose molecules with human safety data, or engineer new reagents that will serve as drug or vaccine prototypes for COVID-19. Competitive projects will have a strong therapeutic or prophylactic hypothesis. Projects at all stages (lead discovery, lead optimization) and modalities (small molecule, large molecule) will be considered provided that the project is driven by developing a therapy or prophylaxis for COVID-19. Basic research and pre-target identification/pre-assay development research are excluded from this RFP. https://chemh.stanford.edu/covid-19-drug-and-vaccine-prototyping
COVID-19 Response: Request for Proposals for Outpatient Studies on Human Subjects: Through this RFP, IMA seeks to support research projects aimed at testing hypotheses in human subjects that, if validated, have the potential to yield powerful new tools for the modeling, diagnosis, or management of COVID-19 in individuals or populations. Competitive projects will have a strong mechanistic basis and will leverage Stanford’s newly established outpatient COVID-19 Clinical and Translational Research Unit (CTRU), where outpatients can be safely tested and/or treated. https://chemh.stanford.edu/covid-19-outpatient-studies-human-subjects
Successful applicants will receive $50K-$100K (total direct) for 6-12 months with the possibility to apply for follow-up funding, contingent upon progress and scientific needs to address the rapidly evolving COVID-19 pandemic. Projects may be fully or partially funded. Projects in the “Outpatient Studies on Human Subjects” track will have access to the COVID-19 CTRU.
Proposals will be reviewed by a faculty panel knowledgeable in translational research. Projects in the “Drug and Vaccine Prototyping” track will be evaluated based on the strength of the evidence for the drug or vaccine hypothesis for the treatment or prevention of COVID-19, novelty, availability of materials and facilities, and achievable goals. Projects in the “Outpatient Studies on Human Subjects” track will be evaluated based on the proposal's potential to advance understanding of the pathogenesis, population biology, diagnosis, or management of COVID-19 in human subjects, access to and use of human subjects or samples, availability of materials and facilities, and achievable goals.
Questions and Contact Info
Elizabeth Sefton, Ph.D.
Scientific Program Manager, Stanford ChEM-H